Category

Articles

Articles
October 16, 2020

9 Steps to Improving Patient Access to Rare and Orphan Drugs

A conversation on eHealth Radio Recently, I had the privilege of a thought-provoking conversation on…
Read More
Caring in the time of COVID
Articles
September 22, 2020

How to Stay Focused on Rare and Orphan Disorders in the Time of COVID

4 Critical Success Factors for Manufacturers Before I became president and CEO of Optime Care,…
Read More
Products first means patients get left behind
Articles
August 20, 2020

Product First Means Patients Left Behind

A tale of too many patients. My family has a long history of alpha-1 antitrypsin…
Read More
scale vs. service
Articles
July 13, 2020

Scale vs. Service? Your rare drug demands both.

When developing a drug commercialization strategy, there’s a misconception that patient service and program scalability are mutually exclusive. The prevailing…
Read More
hub and spoke model for rare and orphan drugs
Articles
June 18, 2020

Revealing 5 hidden truths about using a hub-and-spoke model for rare and orphan drugs

The hub-and-spoke approach has become a standard of drug commercialization. Having a network of patient…
Read More
gaining payer access for rare and orphan drugs
Articles
June 16, 2020

Debunking 6 Myths About Gaining Payer Access for Rare and Orphan Drugs

What works for large patient populations isn’t necessarily a good fit for those with rare…
Read More